As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Renal Cell Cancer Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 125 high prescribing medical oncologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Medical Oncologists 30 20 15 15 15 15 15

Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2013-2022
Patient subpopulations forecasted
  • Clear cell
  • Non-clear cell
Drugs profiled
  • Afinitor
  • AGS-003
  • Avastin
  • IMA-901
  • Inlyta
  • Nexavar
  • Nivolumab
  • Sutent
  • Torisel
  • Votrient

Key Findings

The currently marketed brands in the renal cell cancer (RCC) market (Afinitor, Avastin, Inlyta, Nexavar, Sutent, Torisel, and Votrient) will experience a significant decrease in sales between 2013 and 2022. The total sales revenue of these brands is forecast to peak at $2.5bn in 2018, before decreasing to $719m in 2022. This decline is primarily due to the market entry of generic and biosimilar versions of the leading brands towards the second half of the forecast period.


> Download your free sample > Contact us to find out more


Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726